Not yet independently audited
This page was written from verified sources but has not yet passed the independent citation audit. Treat its claims as provisional.
ADHD guideline registry¶
Last checked: 2026-10-19 (source-specific access limits below; this is not a full registry re-audit)
This registry catalogs guidance documents; recommendation synthesis belongs in guidelines.md. Document-level dates distinguish the original build and audit from later sweep checks; a new sweep date does not imply that every older entry was re-verified.
Master table¶
| Body | Year | Region | Population/scope | Citation | Status |
|---|---|---|---|---|---|
| American Academy of Pediatrics (AAP) | 2000 | US | Pediatric diagnosis/evaluation | AAP. Clinical practice guideline: diagnosis and evaluation. PMID 10836893 | superseded by → AAP 2011 → AAP 2019 |
| American Academy of Pediatrics (AAP) | 2001 | US | School-age treatment | AAP. Treatment of the school-aged child. PMID 11581465 | superseded by → AAP 2011 → AAP 2019 |
| American Academy of Pediatrics (AAP) | 2011 | US | Ages 4–18 diagnosis and treatment | Subcommittee on ADHD. PMID 22003063 | superseded by → AAP 2019 |
| American Academy of Pediatrics (AAP) | 2019 | US | Ages 4–18 diagnosis, evaluation, treatment | Wolraich et al. Pediatrics. PMID 31570648 | current; checked 2026-08-30 |
| Society for Developmental and Behavioral Pediatrics | 2020 | US | Complex pediatric ADHD | Barbaresi et al. PMID 31996577 | current; checked 2026-08-30 |
| NICE CG72 | 2008 | England/Wales | Children, young people and adults | NICE CG72 | superseded by → NG87 |
| NICE NG87 | 2018; amended/surveilled | England/Wales | Lifespan diagnosis and management | NICE NG87 | current; recommendations last updated 13 Sep 2019; last reviewed 23 July 2026 (surveillance: no update on adapted trauma-focused treatment) |
| AADPA / NHMRC | 2022 | Australia | Lifespan identification, diagnosis and treatment | Australian guideline; May et al. PMID 37254562 | current; NHMRC approval originally valid 5 years |
| CADDRA | 2020/2021 | Canada | Lifespan practice guidance and toolkit | Canadian ADHD Practice Guidelines 4.1 | current edition presented by CADDRA |
| German interdisciplinary S3 (AWMF 028-045) | 2026 | Germany | Children, adolescents and adults | AWMF register entry | current version 2.0; supersedes expired 2017/2018 edition |
| Haute Autorité de santé (HAS) | 2024 | France | Children and adolescents; introduces an "ADHD-specialized physician" role | Implementation study citing it: Sürig 2026, PMID 42674891 (HAS site HTTP 403 on 2026-10-12; document not read) | current per secondary source; added 2026-10-12 |
| NHS England Independent ADHD Taskforce | 2025 | England | Service-system reform, all ages (not a clinical guideline) | Final report summarized and critiqued in Khan 2026, PMID 42661151 (erratum published); NHS page did not serve content on 2026-10-12 | policy report; added 2026-10-12 |
| American Society of Clinical Psychopharmacology task force | 2026 | International panel (US-led) | Deprescribing stimulants in adults | Goodman 2026, PMID 42160906 (Delphi, 45 experts) | consensus statement; added 2026-10-12 |
| World Federation of ADHD | 2026 (preprint) | International | Evidence-based consensus statements, lifespan | Faraone 2026, PsyArXiv doi:10.31234/osf.io/w5n9t_v1 (preprint, not peer reviewed); updates the 2021 statement (PMID 33549739) | preprint posted 2026-10-10; added 2026-10-12 |
| Spanish pediatric/cardiology societies | 2020 | Spain | Cardiovascular assessment with ADHD medication | Position statement. PMID 31676246 | current status not independently confirmed |
| European guideline comparison | 2024 | Europe | Pediatric pharmacotherapy recommendations | Overview of European guidelines. PMID 38095716 | secondary synthesis, not issuing guideline |
| International adult-guideline comparison | 2007 | International | Adult diagnosis and treatment | Clinical recommendations in current practice guidelines. PMID 17915083 | historical comparison |
Per-guideline notes¶
AAP 2019¶
- Covers ages 4–18 and updates the 2011 guideline.
- Adds a key action statement on comorbid diagnosis and treatment.
- Maintains a chronic-care and medical-home framing.
- Does not constitute an adult guideline (Wolraich 2019, PMID 31570648).
SDBP complex ADHD 2020¶
- Addresses presentations insufficiently covered by uncomplicated primary-care algorithms.
- Emphasizes coexisting conditions, functional assessment and interdisciplinary care (Barbaresi 2020, PMID 31996577).
NICE NG87¶
- Replaced CG72 and earlier technology/evidence documents.
- Covers recognition, referral, diagnosis, nonpharmacologic and pharmacologic treatment, adherence, monitoring, review and discontinuation.
- Official page includes September 2024 exceptional surveillance.
- NICE records its latest review on 23 July 2026; surveillance did not trigger an update to the recommendations on adapted trauma-focused treatment (NICE NG87, accessed 2026-10-19).
- Recommends ongoing follow-up according to severity irrespective of medication status (NICE NG87, accessed 2026-08-30).
Australian guideline 2022¶
- First national AADPA guideline; published July 2022 and released October 2022.
- Approved by NHMRC and developed with GRADE, multidisciplinary expertise and lived-experience input.
- Explicitly prioritizes everyday function and quality of life as well as symptoms.
- Partly updates and adapts NICE evidence reviews to Australia (AADPA guideline, accessed 2026-08-30; May 2023, PMID 37254562).
CADDRA 4.1¶
- Lifespan guidance with practical forms, follow-up questionnaires and accommodation templates.
- CADDRA states that the edition was updated January 2020/January 2021 publication PDF.
- Earlier editions were issued in 2006, 2008 and 2011, forming a supersession chain (CADDRA overview, accessed 2026-08-30).
German S3¶
- Interdisciplinary evidence- and consensus-based lifespan guidance.
- The 2017/2018 edition is expired, but the AWMF register now hosts version 2.0 materials dated 2026; the registry therefore no longer treats the expired English PDF as the current document.
- Current-version status was rechecked at the AWMF 028-045 register entry on 2026-08-30. Language/version availability should be distinguished from the superseded English translation.
Documented disagreements and gaps¶
- Age coverage differs. AAP is pediatric; NICE, Australia, Canada and Germany use lifespan scopes.
- Health-system assumptions differ. Who diagnoses, prescribes and monitors depends on specialist availability and controlled-drug rules.
- Preschool sequencing differs. Behavioral-first thresholds and when medication is considered are not uniform.
- First-line drug selection differs. Licensing, formulation availability and cost alter stimulant-class recommendations; the evidence network itself shows age-dependent balances (Cortese 2018, PMID 30097390).
- Cardiovascular work-up differs. Routine ECG language varies, although history, examination, pulse and blood-pressure monitoring broadly recur.
- Functional outcomes are endorsed more strongly than they are measured. Acute symptom RCTs dominate the evidence base (Cortese 2018, PMID 30097390).
- Complex comorbidity often falls outside simple algorithms. SDBP created a dedicated complex-ADHD guideline (Barbaresi 2020, PMID 31996577).
- Adult access is structurally uneven. A lifespan recommendation does not create an adult service pathway.
- Female and older-adult evidence remains sparse. Recognition recommendations rely partly on consensus (Hinshaw 2022, PMID 34231220).
- German guidance changed during audit. Version 2.0 (2026) supersedes the expired 2017/2018 edition; English-language availability may lag the German documents.
Watch list¶
| Item | Why it may change | Where to check |
|---|---|---|
| NICE NG87 update | Last reviewed 23 July 2026; recommendations last updated September 2019 | NICE NG87 history/evidence pages |
| Australian guideline approval horizon | Original NHMRC approval was stated as five years from 2022 | AADPA guideline site |
| CADDRA next edition | Version 4.1 remains current; CADDRA reported upcoming guideline updates in July 2026 | CADDRA guideline overview/news |
| German S3 implementation/translation | Version 2.0 is posted in German; translated/current derivative documents may follow | AWMF register 028-045 |
| AAP pediatric revision | 2019 guideline is aging | Pediatrics/AAP guideline portal |
| Adult US national guidance | APSARD announced the final review stage on 27 Aug 2026, with publication "anticipated this fall" (APSARD guidelines page, accessed 2026-10-12); the CDC page returned HTTP 403 on 2026-10-12 | APSARD; PubMed ("APSARD" returned no guideline record on 2026-10-12) |
| Centanafadine scheduling and guideline position | OIRA received a Schedule III interim final rule on 14 October 2026; review is pending, not an effective scheduling decision (OIRA RIN 1117-ZA11, accessed 2026-10-19) | Federal Register effective rule; AAP, NICE, CADDRA, APSARD |
| WFADHD consensus 2026 | Preprint, peer-reviewed version pending | PubMed/Europe PMC |
| Neuromodulation/digital recommendations | Trial activity is growing faster than guideline incorporation | ClinicalTrials.gov and guideline updates |
Search record¶
- PubMed: ADHD guideline, AAP, clinical-practice-guideline appraisal, Australian guideline, European pharmacotherapy guideline overview, adult guideline comparison.
- Official sites re-fetched on 2026-08-30: NICE, AADPA/NHMRC, CADDRA, AWMF and CDC.
- The adult-US negative finding was rerun: CDC's July 2026 page says APSARD is still working on US adult guidelines. This is a dated development-status statement, not a permanent absence claim.
-
2026-10-12 sweep. Re-fetched NICE NG87 (last reviewed 23 July 2026, recommendations unchanged), CADDRA (4.1 edition, January 2020, still presented as the latest), the AADPA guideline site (NHMRC approval statement unchanged), the AWMF 028-045 register entry (HTTP 200) and APSARD (final review stage, unpublished). The CDC and HAS sites returned HTTP 403, and the NHS England taskforce page returned an empty HTTP 202. PubMed searches: "APSARD"; "(American Professional Society of ADHD) AND guideline"; adult ADHD guideline title search (0 records 2025-06-01 to 2026-10-12); "(ADHD OR TDAH) AND France AND guideline"; "ADHD taskforce". The HAS 2024 guideline and the NHS England taskforce report predate this window; earlier builds missed them, and they were back-filled here.
-
2026-10-19 sweep. Official APSARD page still announces final review and anticipated fall publication; no released adult guideline was identified on that page. CADDRA’s overview was retrieved through web browsing after direct HTTP 403 and still presents edition 4.1. NICE remains reviewed 23 July 2026; AADPA still presents its 2022 NHMRC-approved guideline. AAP’s official ADHD landing page still points to its existing pediatric guideline. The AWMF page returned a JavaScript shell, so its document version was not independently re-confirmed. HAS was search-visible but its page fetch failed (TLS failure directly; HTTP 502 through browsing); its recommendations PDF was not appraised. These are access limits, not evidence that no update exists. The PubMed APSARD/guideline query returned one already catalogued deprescribing consensus, not the awaited APSARD adult guideline. Exact queries and source checks are in the sweep manifest.